Erectile dysfunction: Oral pharmacotherapy options

International Journal of Clinical Pharmacology and Therapeutics

Volumn 40, Issue 9, 2002, Pages 393-403

  Vitezic, D ^a   Pelcic, J Mrsic ^a  

^a KBC RIJEKA   (Croatia)

Author keywords

Erectile dysfunction; Oral pharmacotherapy; Other oral agents; Sildenafil

Indexed keywords

APOMORPHINE; CORTICOTROPIN; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; INTERMEDIN; ITRACONAZOLE; KETOCONAZOLE; N ACETYL S NITROSOPENICILLAMINE; NICORANDIL; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PHENTOLAMINE; PINACIDIL; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; SILDENAFIL; TADALAFIL; TESTOSTERONE; TRAZODONE; VARDENAFIL; YOHIMBINE;

ADULT; AGE; AGED; ANXIETY; BACKACHE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DROWSINESS; DRUG ABSORPTION; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; LIVER TOXICITY; MALE; MYALGIA; NAUSEA; NOSE CONGESTION; QUALITY OF LIFE; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; SEXUALITY; SIDE EFFECT; TACHYCARDIA; TREMOR; VERTIGO; VISUAL DISORDER;

EID: 0036727263     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP40393     Document Type: Review

References (72)

1. Pharmacology of penile erection
2. Oral alpha-adrenoceptor blockade as a treatment of erectile dysfunction
3. Oral phentolamine as treatment for erectile dysfunction
4. The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model
5. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
6. Safety and tolerability of apomorphine SL (Uprima)
7. Nitric oxide in the penis: Physiology and pathology
8. Evaluation of sexual satisfaction in partners of men experiencing erectile failure
9. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease
10. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease
11. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials
12. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study
13. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction
14. Oral phentolamine: An alpha-1-, alpha-2-adrenergic antagonist for the treatment of erectile dysfunction
15. Vasomax for the treatment of male erectile dysfunction
16. Oral sildenafil in the treatment of erectile dysfunction
17. Sildenafil causes a dose- and time-dependent downregulation of phosphodiesterase type 6 expression in the rat retina
18. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors
19. Oral phentolamine in nonspecific erectile insufficiency
20. Characterizing the benefit of apomorphine SL (Uprima) as an optimized treatment for representative populations with erectile dysfunction
21. Recovery of erectile function by the oral administration of apomorphine
22. Hemodynamic effects of sildenafil in men with severe coronary artery disease
23. Adrenoceptor-blocking drugs
24. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists
25. Antidepressant agent
26. Dual mechanism of action of nicorandil on rabbit corpus cavernosal smooth muscle tone
27. Viagra and male erectile dysfunction: Prescribing restrictions should be abolished
28. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment
29. Normal and pathological erectile function: The potential clinical role of endothelin-1 antagonists
30. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor
31. Cardiovascular risk and sildenafil
32. Cardiovascular effects of sildenafil citrate and recommendations for its use
33. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: A RigiScan and pharmacokinetics study
34. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study
35. Oral trazodone as empirical therapy for erectile dysfunction: A retrospective review
36. Sildenafil: A review of its use in erectile dysfunction
37. Erectile dysfunction
38. Intimacy and quality of life among sexually dysfunctional men and women
39. Trazodone, a double-blind trial for treatment of erectile dysfunction
40. Clinical guidelines panel on erectile dysfunction: Summary report on the treatment of organic erectile dysfunction
41. Yohimbine in erectile dysfunction: The facts
42. Side-effect profile of sildenafil citrate (Viagra) in clinical practice
43. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells
44. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction
45. Quality of partnership in patients with erectile dysfunction after sildenafil treatment
46. Impotence
47. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease
48. A new era in the treatment of erectile dysfunction
49. Treatment of men with erectile dysfunction with transurethral alprostadil
50. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction
51. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: A double-blind, placebo-controlled study of 329 patients
52. Improvement in emotional well-being and relationships of users of sildenafil
53. The efficacy and tolerability of vardenatil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial
54. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission
55. Sildenafil for treatment of erectile dysfunction in men with diabetes
56. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction
57. Treatment of erectile dysfunction in men with depressive symptoms: Results of placebo-controlled trial with sildenafil citrate
58. Cardiovascular events in users of sildenafil: Results from first phase of prescription event monitoring in England
59. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after single oral dose
60. Relaxation effect of nitric oxide-donor on diabetic penile smooth muscle in vitro
61. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction
62. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms
63. Indications and early results of sildenafil (Viagra) in erectile dysfunction
64. A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction
65. Retinal side-effects of sildenafil
66. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
67. In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions
68. Sildenafil citrate and blood pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist
69. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina
70. Overall cardiovascular profile ofs ildenafil citrate